| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H21NO4 |
| Molecular Weight | 219.278 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO
InChI
InChIKey=UQRORFVVSGFNRO-XFWSIPNHSA-N
InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9+,10-/m1/s1
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Phase 3 study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) b.i.d.; dose adjusted for renal function.
Route of Administration:
Oral
ACTIVE MOIETY
